European Regulator Approves AstraZeneca's COVID-19 shot As Booster

  • The European Medicine Agency has approved AstraZeneca plc's AZN COVID-19 vaccine, Vaxzevria, as a third-dose booster in adults following a committee endorsement last week.
  • The vaccine can now be used as a booster following the two-dose Vaxzevria schedule or by those whom an mRNA vaccine has previously vaccinated, such as the ones from Pfizer Inc PFEBioNTech SE BNTX or Moderna Inc MRNA.
  • Also Read: AstraZeneca In-Licenses New Suite Of COVID-19 Antibody Candidate(s).
  • "Ensuring a longer duration of immune protection is essential to the long-term management of COVID-19 globally, and boosters can address the waning of protection over time that has been seen with all primary vaccine schedules to date," commented Mene Pangalos, executive vice president of biopharmaceuticals R&D at AstraZeneca
  • Price Action: AZN shares are up 0.63% at $66.63 during the premarket session on the last check Monday.
  • Photo by Paul McManus from Pixabay
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBriefsCOVID-19 CoronavirusCOVID-19 VaccineEuropean Medicines Agency
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!